GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Growth Rank

Outlook Therapeutics (FRA:41O) Growth Rank : 0 (As of Jun. 07, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Growth Rank?

Outlook Therapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Outlook Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Outlook Therapeutics (FRA:41O) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Growth Rank
Comparable Companies
VOR BIVI NVCT GRPH FHTX RIGL RPTX VRCA CYDY MRSN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
OTLK:USA 41ON:Germany
Address
485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852
Website
https://www.outlooktherapeutics.com
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Outlook Therapeutics (FRA:41O) Headlines

No Headlines